<DOC>
	<DOC>NCT01068483</DOC>
	<brief_summary>This is a first-in-man, phase I clinical research study with BKM120, a potent and highly specific oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor. The study consists of a dose escalation part followed by a MTD expansion part. Once the MTD has been defined, the MTD expansion part will be opened for enrollment.</brief_summary>
	<brief_title>Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>All patients: Histologicallyconfirmed advanced solid tumors Progressive, recurrent unresectable disease World Health Organization (WHO) Performance status ≤ 2 No history of primary brain tumor or brain metastases MTD Expansion part: Histologicallyconfirmed advanced solid tumors Progressive, recurrent unresectable disease World Health Organization (WHO) Performance status ≤ 2 No history of primary brain tumor; no brain metastases unless asymptomatic and clinically stable for ≥ 3 months Patients with genetic or molecular alteration of the PI3K pathway Prior treatment with a PI3K inhibitor History of or active major depressive episode, bipolar disorder, schizophrenia, or history of suicidal attempt or ideation No clinically manifest diabetes mellitus (treated and/or with clinical signs) No acute or chronic renal disease No acute or chronic liver disease No acute or chronic pancreatitis No unresolved diarrhea No impaired cardiac function or clinically significant cardiac diseases such as ventricular arrhythmia, congestive heart failure, uncontrolled hypertension No acute myocardial infarction or unstable angina pectoris within the past 3 months Not pregnant or nursing and fertile patients must use barrier contraceptives Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Advanced solid tumors</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Endometrium cancer</keyword>
</DOC>